HRP20230639T1 - Pripravak koji sadrži lactobacillus reuteri i citrat za medicinsku primjenu - Google Patents
Pripravak koji sadrži lactobacillus reuteri i citrat za medicinsku primjenu Download PDFInfo
- Publication number
- HRP20230639T1 HRP20230639T1 HRP20230639TT HRP20230639T HRP20230639T1 HR P20230639 T1 HRP20230639 T1 HR P20230639T1 HR P20230639T T HRP20230639T T HR P20230639TT HR P20230639 T HRP20230639 T HR P20230639T HR P20230639 T1 HRP20230639 T1 HR P20230639T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- citrate
- subject
- use according
- lactobacillus reuteri
- Prior art date
Links
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 title claims 8
- 241000186604 Lactobacillus reuteri Species 0.000 title claims 6
- 229940001882 lactobacillus reuteri Drugs 0.000 title claims 2
- 239000000203 mixture Substances 0.000 claims 4
- 241000894006 Bacteria Species 0.000 claims 3
- 206010051606 Necrotising colitis Diseases 0.000 claims 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 3
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 3
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 3
- 230000002028 premature Effects 0.000 claims 3
- 239000008101 lactose Substances 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 239000013020 final formulation Substances 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- 235000003715 nutritional status Nutrition 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Dispersion Chemistry (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Claims (8)
1. Pripravak koji sadrži (i) živu bakteriju Lactobacillus reuteri koja ima sposobnost iskorištavanja citrata kao vanjskog akceptora elektrona i (ii) citrat za upotrebu u terapijskom liječenju ispitanika sa stanjem koje će imati koristi od primjene brže aktivirane žive bakterije Lactobacillus reuteri ili bakterije Lactobacillus reuteri s poboljšanom stopom rasta;
pri čemu su bakterije u pripravku smrznute, liofilizirane ili osušene smrzavanjem, pri čemu se navedeni smrznuti ili liofilizirani pripravak ili pripravak osušen smrzavanjem rekonstituira u odgovarajućoj vodenoj otopini za primjenu u ispitanika prije primjene u navedenog ispitanika;
pri čemu je navedeni ispitanik ljudski ispitanik i novorođenče ili dojenče do jedne godine starosti ili je nedonošče;
pri čemu je navedeno stanje ono stanje u kojem novorođenče, dojenče ili nedonošče ima poteškoća s oralnim hranjenjem, nije sposobno hraniti se dojenjem ili oralno ili zahtijeva parenteralnu ili intravensku prehranu ili kojemu je količina hranjivih tvari u crijevima namjerno ograničena iz medicinskih razloga; i
pri čemu navedena upotreba ne mijenja znatno prehrambeni status novorođenčeta, dojenčeta ili nedonoščeta.
2. Pripravak za upotrebu prema zahtjevu 1, pri čemu je navedeni citrat prisutan u navedenom smrznutom ili liofiliziranom pripravku ili pripravku osušenom smrzavanjem i/ili pri čemu je navedeni citrat prisutan u konačnoj formulaciji za primjenu u navedenog ispitanika.
3. Pripravak za upotrebu prema zahtjevu 1 ili zahtjevu 2, pri čemu je bakterija izložena šećeru ili pripravak nadalje sadrži šećer, pri čemu je poželjno da je navedeni šećer laktoza.
4. Pripravak za upotrebu prema bilo kojem od zahtjeva od 1 do 3, pri čemu je navedeni citrat i po mogućnosti navedeni šećer prisutan u pripravku uspavanih bakterija koje se zatim aktiviraju.
5. Pripravak za upotrebu prema bilo kojem od zahtjeva od 1 do 4, pri čemu je navedeni citrat prisutan u koncentraciji od 0,01 mg/ml do 10,0 mg/ml, poželjno od 0,01 mg/ml do 5,0 mg/ml ili od 0,01 mg/ml do 2,0 mg/ml.
6. Pripravak za upotrebu prema bilo kojem od zahtjeva od 3 do 5, pri čemu pripravak sadrži omjer citrata i laktoze od 1 : 10 do 1 : 600, poželjno od 1 : 60 do 1 : 600 ili od 1 : 30 do 1 : 300.
7. Pripravak za upotrebu prema bilo kojem od zahtjeva od 1 do 6, pri čemu je navedena bakterija Lactobacillus reuteri bakterija Lactobacillus reuteri DSM 17938.
8. Pripravak za upotrebu prema bilo kojem od zahtjeva od 1 do 7, pri čemu je navedeni ispitanik onaj ispitanik koji ima nekrotizirajući enterokolitis (NEC) ili u kojeg postoji rizik od razvoja NEC-a.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562103201P | 2015-01-14 | 2015-01-14 | |
| EP16700501.6A EP3244903B1 (en) | 2015-01-14 | 2016-01-14 | Preparation comprising lactobacillus reuteri and citrate for medical use |
| PCT/EP2016/050694 WO2016113363A1 (en) | 2015-01-14 | 2016-01-14 | A method of activating lactic acid bacteria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230639T1 true HRP20230639T1 (hr) | 2023-09-29 |
Family
ID=55129894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230639TT HRP20230639T1 (hr) | 2015-01-14 | 2016-01-14 | Pripravak koji sadrži lactobacillus reuteri i citrat za medicinsku primjenu |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20170304376A1 (hr) |
| EP (1) | EP3244903B1 (hr) |
| JP (1) | JP6837442B2 (hr) |
| CN (1) | CN107427461B (hr) |
| AU (1) | AU2016208007B2 (hr) |
| BR (1) | BR112017014192B1 (hr) |
| CA (1) | CA2972963C (hr) |
| CL (1) | CL2017001722A1 (hr) |
| CY (1) | CY1126127T1 (hr) |
| ES (1) | ES2952585T3 (hr) |
| HK (1) | HK1247561A1 (hr) |
| HR (1) | HRP20230639T1 (hr) |
| HU (1) | HUE062482T2 (hr) |
| MX (1) | MX2017009247A (hr) |
| PL (1) | PL3244903T3 (hr) |
| RS (1) | RS64392B1 (hr) |
| WO (1) | WO2016113363A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11357803B2 (en) | 2017-09-22 | 2022-06-14 | Iowa State University Research Foundation, Inc. | Probiotic compositions for production of dopamine |
| KR20200001543A (ko) * | 2018-06-26 | 2020-01-06 | 씨제이제일제당 (주) | 구연산염을 포함하는 유산균 동결 보호용 조성물 |
| CN110320840B (zh) * | 2019-07-11 | 2021-06-22 | 四川长虹网络科技有限责任公司 | 一种可降低物联网产品电池电量消耗的方法及系统 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3436581B2 (ja) * | 1994-03-18 | 2003-08-11 | 雪印乳業株式会社 | 乳糖分解酵素活性の高い菌体の製造法 |
| US6506413B1 (en) * | 2001-04-30 | 2003-01-14 | Joseph C. Ramaekers | Compositions for treating animal diseases and syndromes |
| US20030017192A1 (en) * | 2001-06-19 | 2003-01-23 | Hanny Kanafani | Process for producing extended shelf-life ready-to-use milk compositions containing probiotics |
| JP3957132B2 (ja) * | 2001-09-07 | 2007-08-15 | キッコーマン株式会社 | 低濁性醤油乳酸菌の分離用培地、同培地を用いる低濁性醤油乳酸菌の分離法及び同乳酸菌を用いる清澄度の高い醤油の製造法 |
| FR2859217B1 (fr) * | 2003-09-03 | 2005-11-11 | Rhodia Chimie Sa | Activateur pour ferment a base de bacteries lactiques et procede de preparation d'un produit mettant en oeuvre ledit activateur |
| JP2007330157A (ja) * | 2006-06-15 | 2007-12-27 | Obihiro Univ Of Agriculture & Veterinary Medicine | 乳酸菌及び乳酸菌由来物の癌細胞増殖抑制作用および炎症性サイトカイン抑制作用を測定する方法 |
| US8617537B2 (en) * | 2008-06-10 | 2013-12-31 | Biogaia Ab | Controlled activation of the reuterin-production machinery of lactobacillus |
| FR2967070B1 (fr) * | 2010-11-05 | 2013-07-05 | Oreal | Acide gras monoinsature pour prevenir et/ou traiter les imperfections du teint de la peau |
| EP2408171A1 (en) * | 2010-07-16 | 2012-01-18 | Research In Motion Limited | Application programming interface for mapping application |
| BR112013016914A2 (pt) * | 2010-12-31 | 2019-09-24 | Abbott Lab | combinação simbiótica de probióticos e oligossacarídeos do leite humano para promover o crescimento de microbiota benéfica |
| JP5622110B2 (ja) * | 2011-02-21 | 2014-11-12 | 株式会社農 | 新規乳酸菌 |
| JP6051112B2 (ja) * | 2013-06-05 | 2016-12-27 | 公立大学法人大阪府立大学 | 白金族金属の回収方法 |
| CN104206539A (zh) * | 2014-08-14 | 2014-12-17 | 澳优乳业（中国）有限公司 | 一种益生菌婴幼儿奶粉 |
-
2016
- 2016-01-14 CN CN201680005682.2A patent/CN107427461B/zh active Active
- 2016-01-14 PL PL16700501.6T patent/PL3244903T3/pl unknown
- 2016-01-14 JP JP2017555837A patent/JP6837442B2/ja active Active
- 2016-01-14 US US15/320,996 patent/US20170304376A1/en active Pending
- 2016-01-14 AU AU2016208007A patent/AU2016208007B2/en active Active
- 2016-01-14 BR BR112017014192-2A patent/BR112017014192B1/pt active IP Right Grant
- 2016-01-14 HU HUE16700501A patent/HUE062482T2/hu unknown
- 2016-01-14 EP EP16700501.6A patent/EP3244903B1/en active Active
- 2016-01-14 HR HRP20230639TT patent/HRP20230639T1/hr unknown
- 2016-01-14 WO PCT/EP2016/050694 patent/WO2016113363A1/en active Application Filing
- 2016-01-14 MX MX2017009247A patent/MX2017009247A/es unknown
- 2016-01-14 ES ES16700501T patent/ES2952585T3/es active Active
- 2016-01-14 CA CA2972963A patent/CA2972963C/en active Active
- 2016-01-14 RS RS20230608A patent/RS64392B1/sr unknown
-
2017
- 2017-06-28 CL CL2017001722A patent/CL2017001722A1/es unknown
-
2018
- 2018-05-30 HK HK18107030.7A patent/HK1247561A1/zh unknown
-
2023
- 2023-07-11 CY CY20231100325T patent/CY1126127T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3244903A1 (en) | 2017-11-22 |
| BR112017014192B1 (pt) | 2022-02-01 |
| AU2016208007A1 (en) | 2017-07-06 |
| JP6837442B2 (ja) | 2021-03-03 |
| CN107427461A (zh) | 2017-12-01 |
| CL2017001722A1 (es) | 2018-04-06 |
| BR112017014192A2 (pt) | 2018-03-06 |
| CA2972963A1 (en) | 2016-07-21 |
| ES2952585T3 (es) | 2023-11-02 |
| PL3244903T3 (pl) | 2023-08-14 |
| CY1126127T1 (el) | 2023-11-15 |
| US20170304376A1 (en) | 2017-10-26 |
| EP3244903B1 (en) | 2023-06-07 |
| JP2018503684A (ja) | 2018-02-08 |
| AU2016208007B2 (en) | 2021-09-09 |
| HK1247561A1 (zh) | 2018-09-28 |
| EP3244903C0 (en) | 2023-06-07 |
| RS64392B1 (sr) | 2023-08-31 |
| CN107427461B (zh) | 2021-04-13 |
| CA2972963C (en) | 2023-03-14 |
| WO2016113363A1 (en) | 2016-07-21 |
| HUE062482T2 (hu) | 2023-11-28 |
| MX2017009247A (es) | 2017-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2960750T3 (es) | Oligosacáridos de la leche humana para el tratamiento de infecciones agudas del aparato respiratorio | |
| ES2431936T3 (es) | Mezcla sinergística de beta-galacto-oligosacáridos con enlaces beta-1,3 y beta-1,4/1,6 | |
| CN102573517B (zh) | 稳定的增稠剂制品 | |
| ES2578261T3 (es) | Lactobacillus johnsonii para prevenir infecciones postoperatorias | |
| CN104206539A (zh) | 一种益生菌婴幼儿奶粉 | |
| CA2897363C (en) | Baby food composition comprising viable propionic acid-producing bacteria | |
| BR112020021775A2 (pt) | composições simbióticas | |
| CN103458889A (zh) | 包括支链脂肪酸的用于创口愈合的营养组合物 | |
| PH12017502182A1 (en) | Nutritional compositions and infant formulas comprising bifidobacterium animalis ssp. lactis and optionally a mix of oligosaccharides for inducing a gut microbiota close to the one of breast fed infants | |
| CN105410932A (zh) | 一种肿瘤免疫型营养组合物及其应用 | |
| JP2016505024A5 (hr) | ||
| JP2017515881A5 (hr) | ||
| HRP20230639T1 (hr) | Pripravak koji sadrži lactobacillus reuteri i citrat za medicinsku primjenu | |
| JP2015533509A5 (hr) | ||
| BR112017023636B1 (pt) | Composição oral | |
| JP2011116666A (ja) | 乳酸菌発酵ローヤルゼリーを含有する抗ストレス剤及びその製造方法 | |
| WO2011133681A3 (en) | Low/high dose probiotic supplements and methods of their use | |
| ES2858799T5 (es) | Composición nutricional fermentada para sujetos alérgicos a las proteínas de leche de vaca | |
| JP2013505720A (ja) | テアニン及び外因性ヌクレオチドを含む栄養組成物 | |
| CN107668458A (zh) | 一种可改善女性痛经的固体饮料 | |
| RU2629814C1 (ru) | Препарат для лечения желудочно-кишечных болезней телят, протекающих с признаками диареи | |
| RU2589843C2 (ru) | Средство для лечения кишечных инфекций и состояний, вызванных дисбактериозом, "биобаланс а" | |
| Floch | Gender in probiotic use | |
| WO2014163031A1 (ja) | 即効性の整腸剤 | |
| Roy et al. | Postbiotics: potential applications in early life nutrition and beyond |